{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:05:07Z","timestamp":1790769907376,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1097\/mca.0000000000000521","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T14:19:02Z","timestamp":1499437142000},"page":"577-587","source":"Crossref","is-referenced-by-count":18,"title":["Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder"],"prefix":"10.1097","volume":"28","author":[{"given":"Kiyoshi","family":"Iida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemasa","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kawauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210204","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.02.002","article-title":"Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study","volume":"140","author":"Tofler","year":"2016","journal-title":"Thromb Res"},{"key":"R2-9-20210204","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0038-1646175","article-title":"Plasminogen activator inhibitor 1 and atherothrombosis","volume":"70","author":"Juhan-Vague","year":"1993","journal-title":"Thromb Haemost"},{"key":"R3-9-20210204","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(87)93050-9","article-title":"Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction","volume":"2","author":"Hamsten","year":"1987","journal-title":"Lancet"},{"key":"R4-9-20210204","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cca.2011.10.009","article-title":"Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina","volume":"413","author":"Tretjakovs","year":"2012","journal-title":"Clin Chim Acta"},{"key":"R5-9-20210204","doi-asserted-by":"crossref","first-page":"629","DOI":"10.5551\/jat.7922","article-title":"The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism","volume":"18","author":"Matsuzawa","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"R6-9-20210204","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.bbalip.2011.09.021","article-title":"Lipolysis of triglyceride-rich lipoproteins, vascularinflammation, and atherosclerosis","volume":"1821","author":"Schwartz","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"R7-9-20210204","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"R8-9-20210204","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/01.ATV.0000154144.73236.f4","article-title":"Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Qu\u00e9bec Cardiovascular Study","volume":"25","author":"St-Pierre","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R9-9-20210204","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11883-008-0059-2","article-title":"Is it LDL particle size or number that correlates with risk for cardiovascular disease?","volume":"10","author":"Superko","year":"2008","journal-title":"Curr Atheroscler Rep"},{"key":"R10-9-20210204","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.2337\/dc12-2388","article-title":"Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial.","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"key":"R11-9-20210204","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5551\/jat.12.67","article-title":"Measurement of small dense low-density lipoprotein particles","volume":"12","author":"Hirano","year":"2005","journal-title":"J Atheroscler Thromb"},{"key":"R12-9-20210204","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jjcc.2013.06.018","article-title":"Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size","volume":"63","author":"Tani","year":"2014","journal-title":"J Cardiol"},{"key":"R13-9-20210204","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10157-006-0453-4","article-title":"Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease","volume":"11","author":"Imai","year":"2007","journal-title":"Clin Exp Nephrol"},{"key":"R14-9-20210204","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0009-9120(03)00117-6","article-title":"Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula","volume":"36","author":"Sniderman","year":"2003","journal-title":"Clin Biochem"},{"key":"R15-9-20210204","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1203\/00006450-200302000-00021","article-title":"Fibrinolytic system in adolescents: response to venous occlusion stress tests","volume":"53","author":"Monagle","year":"2003","journal-title":"Pediatr Res"},{"key":"R16-9-20210204","doi-asserted-by":"crossref","first-page":"858293","DOI":"10.1155\/2014\/858293","article-title":"Functional stability of plasminogen activator inhibitor-1","volume":"2014","author":"Yasar Yildiz","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"R17-9-20210204","doi-asserted-by":"crossref","first-page":"e0171271","DOI":"10.1371\/journal.pone.0171271","article-title":"The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays","volume":"12","author":"Pieters","year":"2017","journal-title":"PLoS One"},{"key":"R18-9-20210204","first-page":"85","article-title":"The proposed standardization of sample preparation for clotting time assays","volume":"17","author":"Ieko","year":"2016","journal-title":"Jpn Soc Lab Hematol"},{"key":"R19-9-20210204","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/07420529109059170","article-title":"Circadian variation of fibrinolytic activity in blood","volume":"8","author":"Andreotti","year":"1991","journal-title":"Chronobiol Int"},{"key":"R20-9-20210204","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1536\/ihj.52.343","article-title":"Low-density lipoprotein cholesterol\/apolipoprotein B ratio may be a useful index that differs in statin-treated patients with and without coronary artery disease: a case control study","volume":"52","author":"Tani","year":"2011","journal-title":"Int Heart J"},{"key":"R21-9-20210204","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5551\/jat.10.186","article-title":"Assessment of LDL particle size by triglyceride\/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia","volume":"10","author":"Maruyama","year":"2003","journal-title":"J Atheroscler Thromb"},{"key":"R22-9-20210204","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/01.ATV.19.3.605","article-title":"Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study","volume":"19","author":"Festa","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R23-9-20210204","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1253\/circj.CJ-11-1519","article-title":"Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan","volume":"76","author":"Saito","year":"2012","journal-title":"Circ J"},{"key":"R24-9-20210204","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jacl.2013.08.001","article-title":"High-density lipoproteins: a consensus statement from the National Lipid Association","volume":"7","author":"Toth","year":"2013","journal-title":"J Clin Lipidol"},{"key":"R25-9-20210204","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2015.03.089","article-title":"Innovative pharmaceutical interventions in cardiovascular disease: focusing on the contribution of non-HDL-C\/LDL-C-lowering versus HDL-C-raising: a systematic review and meta-analysis of relevant preclinical studies and clinical trials","volume":"763","author":"K\u00fchnast","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"R26-9-20210204","first-page":"279","article-title":"Association of the low-density lipoprotein cholesterol\/high-density lipoprotein cholesterol ratio and body mass index with coronary plaque regression","volume":"12","author":"Tani","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"R27-9-20210204","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(08)60768-0","article-title":"Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies","volume":"371","author":"Mazzone","year":"2008","journal-title":"Lancet"},{"key":"R28-9-20210204","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2005.05.069","article-title":"Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound","volume":"96","author":"Tani","year":"2005","journal-title":"Am J Cardiol"},{"key":"R29-9-20210204","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00380-015-0678-9","article-title":"Association of lecithin-cholesterol acyltransferase activity measured as a serum cholesterol esterification rate and low-density lipoprotein heterogeneity with cardiovascular risk: a cross-sectional study","volume":"31","author":"Tani","year":"2016","journal-title":"Heart Vessels"},{"key":"R30-9-20210204","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/eurheartj\/ehn387","article-title":"Adipose tissue dysfunction in obesity, diabetes, and vascular diseases","volume":"29","author":"Hajer","year":"2008","journal-title":"Eur Heart J"},{"key":"R31-9-20210204","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.CIR.91.3.764","article-title":"Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo","volume":"91","author":"Nordt","year":"1995","journal-title":"Circulation"},{"key":"R32-9-20210204","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s005920170016","article-title":"Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat","volume":"38","author":"Pandolfi","year":"2001","journal-title":"Acta Diabetol"},{"key":"R33-9-20210204","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0002-9343(99)00240-5","article-title":"Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects","volume":"107","author":"Carmassi","year":"1999","journal-title":"Am J Med"},{"key":"R34-9-20210204","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.amjcard.2014.11.044","article-title":"Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus","volume":"115","author":"Tani","year":"2015","journal-title":"Am J Cardiol"},{"key":"R35-9-20210204","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/1520-7560(200005\/06)16:3<192::AID-DMRR114>3.0.CO;2-G","article-title":"Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance","volume":"16","author":"Bastard","year":"2000","journal-title":"Diabetes Metab Res Rev"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:41:56Z","timestamp":1620960116000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019501-201711000-00009"}},"subtitle":["a pilot cross-sectional study"],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000521","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}